84 results about "Lamotrigine" patented technology

The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously; may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients; and may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, other active ingredients, and DMSO or Sterile Water for Irrigation. In another aspect, the present embodiments relate to methods of compounding medications and transdermal creams or gels.

The invention provides a medicine solution suitable for oral administration. The preparation method for a lamotrigine oral solution comprises lamotrigine or a lamotrigine eutectic matter which can improve the solubility, a suitable medicinal solvent system, one or multiple flavour masking agents, one or multiple preservatives, one or multiple matters selecting from lactic acid, acetic acid, tartaric acid and citric acid and the like. The lamotrigine oral solution has the PH value ranging from two to four. The lamotrigine oral solution can be used for treating epilepsy and bipolar disorder, especially for a patient who suffers from dysphagia and for improving the compliance of a patient sufferring from the bipolar disorder.

The invention discloses a lamotrigine oral liquid preparation. Each 1000ml of the lamotrigine oral liquid preparation contains 0.4-2g of lamotrigine, 10-500g of a sweetener, 0.5-1.5ml of a perfume, 0.5-1.5g of an antiseptic, 0.001-0.1g of a coloring agent, a proper amount of a pH adjusting agent, and the balance of purified water, and the pH value of the lamotrigine oral liquid preparation is 2.5-4.0. The invention also discloses a preparation method of the lamotrigine oral liquid preparation. The lamotrigine oral liquid preparation can effectively cover the bad taste of medicines, can be conveniently swallowed, can be accepted by patients (especially children), and has good administration compliance.

A method for determining blood-medicine concentration of antiepileptic medicine includes pre-treating sample to be determined and separating pretreated sample by acidic mobile phase in chromatographic column then utilizing ultraviolet detector to simultaneously detect quantitative concentration of phenobarbital, lamotrigine, oxcarbazepin and adipomono- oxcarbazepin as antiepileptic medicine.

The invention provides a synthetic method of drug lamotrigine for curing bipolar disorder and epilepsy. 2-cyano-(2, 3-dichlorophenyl)-2-guanidine amino acetonitrile and n-propyl alcohol (CH3CH2CH2OH) solvent are used as a raw material, and the lamotrigine is generated through one-step cyclization reaction in a reaction tank. The synthetic method of the drug lamotrigine includes material preparation, crude product manufacturing, purification, filtration and drying. The raw material of the synthetic method comprises only the 2-cyano-(2, 3-dichlorophenyl)-2-guanidine amino acetonitrile as a starting material and the n-propyl alcohol (CH3CH2CH2OH) solvent and has no strong acid, strong base and other toxic substances, the lamotrigine is manufactured through the one-step cyclization reaction, and therefore the synthetic method is small in reaction steps, high in yield, simple and convenient to operate and high in raw material utilization rate, avoids using toxic and harmful substances in abundance, reduces production cost remarkably, and has high social benefits and social benefits.

The present invention provides a pharmaceutical composition comprising a plurality of lamotrigine particles having a specific surface area of from about two to about three and a half meters per gram. Pharmaceutical compositions falling within the surface area criteria for the lamotrigine particles include those having a particle diameter equal to or less than about 100 μm, preferably about 50 μm, and most preferably 10 μm. The pharmaceutical composition can be formulated into a wide variety of dosage forms.

The invention aims to provide a lamotrigine sustained release tablet, which is stable in drug release and higher in medication safety and is characterized by comprising lamotrigine with the effective therapeutic dose and physiologically acceptable pharmaceutical accessories. The lamotrigine sustained release tablet disclosed by the invention has the characteristics of being convenient for drug delivery, lasting in effect, stable in curative effect, low in toxic and side effect and the like.

The invention discloses a biomarker for forecasting severe drug-induced cutaneous adverse reaction of a child patient and an application. The biomarker is capable of forecasting the risk of severe cutaneous adverse reaction of the child patient using beta-lactam antibiotics such as penicillin, cephalosporin, carbamazepine, lamotrigine, oxcarbazepine, phenytoin, allopurinol, nevirapine, abacavir, methazolamide and dapsone.

A method for preparing 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine, commonly known as lamotrigine, is disclosed. A method of preparing the intermediate, 2,3-dichlorobenzoyl chloride, by photochlorination of 2,3-dichlorobenzotrichloride followed by hydrolysis is also disclosed. The intermediate may then be used in the preparation of lamotrigine.

The invention provides a method for detecting lamotrigine in breast milk. The method comprises the following steps: 1) preparation of a tested object: taking the test breast milk, adding ethyl acetate with five times of volume and uniformly mixing the materials, performing centrifugation, taking an ethyl acetate layer, drying the ethyl acetate layer, redissolving a mobile phase as the tested object; and 2)detection: taking the tested object in the step 1) and detecting by high performance liquid chromatography, wherein the detection condition is characterized in that a stationary phase is C18 chromatographic column; a mobile phase is a methanol-inorganic salting solution, the volume ratio of the stationary phase to the mobile phase is 17:83, the pH value of the inorganic salting liquid is 4.5, and the detection wavelength is 210 nm. The method provided by the invention can accurately detect levetiracetam in breast milk, has the advantages of rapid and simple process, strong specialization, high sensitivity and good stability, can be used for clinically detecting the concentration of levetiracetam, and provides guidance for woman with breast nursing who administrates levetiracetam.

The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients. For instance, the transdermal cream may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, and/or other active ingredients. In another aspect, the present embodiments relate to methods of compounding medications and transdermal creams or gels.

Water dispersible compressed tablets and a process for preparing the same. The tablet comprising about 0.1 to 50% w/w of lamotrigine or its pharmaceutically acceptable salts, solvates, hydrates or polymorphs, about 5 to about 50% w/w of a water-soluble diluent(s), about 15 to about 70% w/w of a water swellable diluent(s), optionally one or more pharmaceutically acceptable adjuvants, wherein the ratio of water-soluble diluent(s) to water swellable diluents(s) is from about 0.6 to about 0.9 and said composition is essentially free of disintegrant, superdisintegrant and swellable clay.

The invention is directed to novel crystalline forms of lamotrigine. These novel crystalline forms of lamotrigine have improved dissolution and in-vivo absorption profile, as compared to pure lamotrigine. These novel crystalline forms of lamotrigine provide a substantial increase in the blood concentration of lamotrigine, as compared to pure lamotrigine when administered to a subject. These novel crystalline forms of lamotrigine also provide a slower, steady build up of lamotrigine blood concentration suitable for sustained release of lamotrigine in-vivo, as compared to pure lamotrigine.

The present invention relates to controlled release formulations comprising lamotrigine and process for preparation thereof.

The invention relates to a compound lamotrigine subcutaneous implantable controlled-release glue rod, which contains lamotrigine, alprazolam and a controlled-release agent. The compound lamotrigine subcutaneous implantable controlled-release glue rod can be implanted into a loose part of the lower abdominal wall subcutaneous tissues of a patient by using small incision and trocar introduction, after the patient obtains satisfactory curative effect from acute treatment; the controlled-release glue rod is lasting in curative effect, economical and practical, and the curative effect can be controlled at about 1 year for each implantation; and the drug is guided by the controlled-release agent and releases slowly at a uniform speed through a medical silica gel film wall, so as to guarantee stable and effective blood drug level and achieve the purpose of therapy maintenance. The controlled-release glue rod is applicable to patients with all types of epilepsy (induced mental disorders), mood disorders and other indications for lamotrigine treatment.

The invention relates to novel medicines and application, and particularly provides application of a composition of ginsenoside C-K and lamotrigine in preparation of anti-epilepsy medicines. Animal experiments prove that the composition of ginsenoside C-K and lamotrigine can be used for remarkably prolonging the incubation period of epilepsy, reducing the attack strength of epilepsy, shortening the duration of epilepsy and reducing the weight loss after attack, and indicate that the composition of ginsenoside C-K and lamotrigine can be used for relieving or controlling attack of epilepsy and inhibiting occurrence and development of epilepsy, and adverse medicine response caused by lamotrigine can be alleviated by reducing the dosage of lamotrigine.

The invention relates to processes for the preparation of piperidylmethyl-indanones, and to the use of these compounds as intermediates for the preparation of benzyl-piperidylmethyl-indanones which are active compounds for the treatment of CNS disorders. The invention also relates to a process for the preparation of donepezil or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions that include the donepezil or a pharmaceutically acceptable salt thereof.

The invention discloses a method for preparing lamotrigine. Under the acid condition, aminoguanidine bicarbonate reacts with 2,3-dichlorobenzoylcyanide to generate an intermediate compound Schiff base. The method is characterized in that the intermediate compound Schiff base is directly heated in an alkaline carrier through microwaves to carry out cyclization reaction to obtain a lamotrigine product. The method disclosed by the invention has the advantages of high yield, few steps and high utilization rate of raw materials, and is simple and convenient in operation; by adopting a microwave-promoted solid-phase reaction to carry out cyclization, materials which are not environment-friendly are prevented from being used widely, thereby being more beneficial to environment protection, obviously lowering the production cost, and improving the production efficiency; and the invention has obvious social and economic benefits.